Kidney Function Tests Market Size, Share, and COVID-19 Impact Analysis, By Test Type (Blood Test {Serum Creatinine, Blood Urea Nitrogen (BUN), and Glomerular Filtration Rate (GFR)}, Urine Test {Urinalysis, Albumin Creatinine Ratio, Microalbuminuria, and Others}, and Others), By Sample Type (Blood, Urine, and Others), By Products (Dipsticks and Reagents & Kits), By End-Users (Hospitals & Clinics, Clinical Laboratories, and Others), and Regional Forecast, 2026-2034

The global kidney function tests market size was valued at USD 1.03 billion in 2025. The market is projected to grow from USD 1.1 billion in 2026 to USD 1.85 billion by 2034, exhibiting a CAGR of 6.78% during the forecast period.

Kidney function tests are used to evaluate the normal functioning of the kidney by performing the test using various sample types. The majority of these tests measure the glomerular filtration rate (GFR) of the kidney. GFR assessment is done to evaluate the efficient working of the kidneys. The abnormal functioning of the kidneys is due to several factors such as diabetes, high blood pressure (hypertension), heart diseases, family history of kidney failure, and others.

An increase in the number of patients suffering from chronic kidney disease (CKD) is one of the major factors contributing to the kidney function test market growth. CKD is more prevalent in older individuals, women, and in people suffering from diabetes mellitus and hypertension.

• For instance, according to data published by Kidney International Supplements in April 2022, CKD is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals and it is one of the most prominent causes of death, and suffering in the 21st century.

Furthermore, government and non-government entities are actively investing in the development of therapeutics for chronic kidney diseases, which is expected to fuel the growth in the market.

• For instance, according to data published by the Clinical Journal of the American Society of Nephrology in May 2018, The Indian Government, in its Healthcare Union Budget 2016, announced the plan for stand-alone hemodialysis (HD) centers for patients with End-stage Kidney Disease (ESKD), and the National Dialysis Services Program proposes that each district hospital offer HD services in a Public Private Partnership model. 

Furthermore, factors such as an increased incidence of chronic kidney disease, technological advances in diagnostic tests for kidney diseases, and the growing need for early detection are also driving the market growth. 

• For instance, according to data published by Austhe tralian Institute of Health and Welfare in August 2022, around 17,700 deaths were reported in Australia, in 2020 due to chronic kidney diseases. Furthermore, the same source stated that, 76% of these deaths had CKD as a relative cause of death. 

Impact of COVID-19 on the Kidney Function Test Market

The kidney function test market witnessed a positive impact in the year 2020 by the COVID-19 pandemic due to an increase in the number of cases of kidney damage. Patients with kidney disease are at increased risk of serious complications and outcomes get worsen when infected with COVID-19. Several ongoing clinical studies on the long-term effects of COVID-19 are providing further evidence of kidney damage.

• For instance, according to article published by Randox Laboratories, The National Institute for Health and Care Excellence (NICE) recommends that all COVID-19 patients be screened for acute kidney injury on hospitalization and have their condition monitored during their stay. Therefore to address this issue Randox utilizes patented Biochip technology for better COVID-19 risk stratification while monitoring treatment efficacy. 

The demand for kidney function tests was increased due to an increase in kidney damage cases associated with COVID-19 infection, which resulted in the growth of the kidney function test market.

Key Insights

The report will cover the following key insights:

• Prevalence of Chronic Kidney Diseases - by Key Countries/Regions, 2022
• Overview of Regulatory Scenario – by Key Countries/Regions, 2022
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Impact of COVID-19 on the Kidney Function Test Market

Analysis by Products

Based on product, the dipsticks segment accounted for a significant proportion of the kidney function test market in 2022. The growth is mainly attributed to the constant innovation and the development of new diagnostic methods to estimate the proper functioning of the kidney which is further associated with chronic kidney diseases.

• For instance, in April 2023, as per the article published by Oxford University Press on behalf of the American Medical Informatics Association, the machine-learning models are used to detect CKD without blood collection, predicting an estimated glomerular filtration rate (eGFR) using a urine dipstick test.
• Moreover, in October 2018, according to an article published by Verdict Media Limited, Siemens Healthineers  announced a collaboration with Healthy.io the Israeli firm, to improve kidney disease monitoring by enabling at-home urine testing with the help of dipsticks.

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America is anticipated to gain a significant market share in the kidney function test market during the forecast period. The major factors driving the growth of the market are the rising prevalence of chronic kidney disease, the presence of a well-established healthcare infrastructure, and availability of technologically advanced diagnostic tests in the region. Increasing population burden due to CKD is a key factor driving the market growth. 

• For instance, in July 2022, as per the data published by, Centers for Disease Control and Prevention, It is estimated that more than 1 in 7 adults in the U.S., or 15%, or 37 million people, have CKD.

In addition, the robust growth of technology in the healthcare sector and increasing product launches, coupled with the rising level of research and development are driving the growth of the market in North America.

Key Players Covered

The report will include the profiles of key players such as Abbott, Quest Diagnostics Incorporated, Abbexa, Beckman Coulter, Abcam plc., Anamol Laboratories Pvt. Ltd., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Randox Laboratories Ltd., Gentian Diagnostics ASA, and others.

Segmentation

Key Industry Developments

• August 2022: Bloom Diagnostics introduced a new kidney test for the quantitative measurement of cystatin C in whole blood.
• September 2021: the American Society of Nephrology and the National Kidney Foundation (NKF) released a new report on an innovative way to diagnose kidney diseases.
• October 2018: Siemens Healthineers announced a worldwide partnership with Israeli firm Healthy.io to improve kidney disease monitoring by enabling at-home urine testing.
• April 2018: the National Kidney Foundation (NKF), Geisinger, and Healthy.io announced the launch of a novel clinical trial using a smartphone-enabled home urinalysis device CKD among patients with high blood pressure.